Archives: Speakers

Melanie Morrison

Melanie Morrison is a leader in Clinical Development and Project Management with 20 years of experience driving corporate transitions from early stage to late stage clinical development organizations.  Ms. Morrison is currently Vice President, Clinical Operations, Data & Systems at Nuvation Bio, a biotechnology company focusing on the foremost unmet needs in oncology.  Prior to Nuvation, Ms. Morrison was at Aduro Biotech, where she served as interim Project Team Leader for one of its lead oncology assets, Chief of Staff, and Vice-President, Process Optimization.  She also served as the Vice President, Oncology Platform Lead at Immune Design (now part of Merck & Co) leading the Clinical Operations and Project Management groups as well as managing the core team for its oncology assets. Ms. Morrison was Vice President, Clinical Operations for Medivation prior to its acquisition by Pfizer.  In this role, she oversaw the development and execution of clinical development plans, functional resourcing for a team of approximately 100 employees, and budgeting for 40+ studies. Ms. Morrison was at Genentech from 1999 to 2007 in roles with increasing responsibility within Clinical Operations and Project Management supporting Genentech’s oncology pipeline. She holds a Master of Science in Health Sciences from The George Washington University School of Medicine and Health Sciences and a Bachelor of Science from UC Davis. She holds numerous certifications in regulatory affairs, project management, clinical research management, and public health from such organizations as UC Berkeley, UC Santa Cruz, and UNC Chapel Hill. Ms. Morrison is also an Executive Scholar in Leadership from the Kellogg School of Management

Shad Ayoub

With over 13 years in the pharmaceutical services industry and over 20 years of software development experience, Shad has a strong foundation for delivering real value to clients and partners. In his current role as Director, Vault Clinical at Veeva, Shad drives the development of product and market strategy for Veeva Vault eTMF, CTMS, and Study Startup.

Shad aspires to help bring the next generation of clinical development applications and capabilities to the life sciences industry. With a degree in Business Administration and an MBA, Shad’s expertise in software development and project management in the pharmaceutical industry provides him with the ability to analyze the most demanding business needs in life sciences.

Dr. Wolfgang Goetz

Dr. Goetz is an accomplished clinician, scientist, and cardiac surgeon with a decade of clinical experience. He combines profound practical experience with his passion for curing heart valve disease. His main interest is developing innovative treatments for structural heart valve diseases. He started his career as a cardiac surgeon at the University Hospital in Regensburg, Germany. After continuing clinical practice in Germany, Dr. Goetz went to Singapore in 2005-2006 to lead a research project for developing a surgical autologous heart valve prosthesis that is made from a patient’s own pericardium. This priceless valve prosthesis was implanted in humans in Asia. In 2005 he founded EndoCor Inc. in Singapore for the development of percutaneous heart valve prostheses. Back in Germany, Dr. Goetz worked at the German Heart Center in Munich. Within one year he qualified as an associated professor (Habilitation). At the same time, he did set up a clinical trial for the implantation of transcatheter heart valve prostheses.

Having gained comprehensive knowledge in cardiac surgery, the development of heart valve prostheses and, finally, the new technology of transcatheter heart valves, he decided in 2009 to give up a very successful career as a cardiac surgeon and to start-up Transcatheter Technologies GmbH to develop a transcatheter heart valve system that is designed to increase the safety and durability of aortic valve implantation. The proprietary technology was acquired by Venus Medtech (Hangzhou, China) in 2016.

Afterwards, Dr. Goetz became Partner of medifundo Life Science Investments. In 2018 Dr. Goetz founded Prima Medical Technologies GmbH and spun-off three technology companies: Artract Medical, Semiflow Medical and Venock Medicial Inc. in the USA with the subsidiary Venock Medical GmbH, in Germany

Dr. Sabine Hauck

Sabine Hauck is Vice President Research & Development at Munich-based biotech company LEUKOCARE. She has 20 years of experience in biotech industry, in which she held various positions in development, quality assurance and regulatory affairs. For about 10 years during this time she was responsible for clinical trial materials that consisted of a Medicinal Product and a Medical Device, and during this time she acquired a lot of experience in the use of Medical Devices in clinical trials and in development of combination products. In the current position Sabine Hauck is responsible for R&D activities at LEUKOCARE AG. In this role she oversees the customer projects and internal development projects including the algorithm-based formulation development approach at LEUKOCARE AG.

Catrin Argyle

Catrin Argyle is a Senior Clinical Research Associate at Ava AG in Switzerland. Ava AG is a digital women`s health company with a mission to advance women`s reproductive health by bringing together artificial intelligence and clinical research. Catrin joined the company in 2018 and is involved in the management of clinical trials for wearable medical devices. Her work involves exploring novel methodologies to increase clinical trial efficiency whilst maintaining quality and compliance. In addition to this, Catrin has experience with EU medical device submissions and MDR compliance.

 

Catrin has a background in the pharmaceutical industry, having previously worked in site management on phase II/III trials at IQVIA. Catrin holds an MSc in Reproductive Science and Women`s Health from University College London.